Enfanos Announces the Formation of Scientific Advisory Board
- zmherbst
- 2 hours ago
- 2 min read
Scientific innovation in rare disease research is at the heart of Enfanos’ leadership. Today, we are pleased to announce the formation of our Scientific Advisory Board, bringing together internationally recognized experts whose careers have shaped the fields of lysosomal storage disorders, analytical chemistry, rare disease research, public health genetics, and translational science.
The Scientific Advisory Board is chaired by Professor Michael H. Gelb, PhD, whose pioneering research in tandem mass spectrometry has significantly advanced scientific understanding of lysosomal storage disorders and helped establish many of the analytical approaches that continue to influence newborn screening research around the world.
Joining Professor Gelb are three distinguished scientists and leaders:
Amy Gaviglio, MS, CGC is widely recognized for her leadership in public health genetics and newborn screening programs. Throughout her career, she has worked to strengthen collaboration among researchers, laboratories, clinicians, patient advocacy organizations, and public health agencies while advancing policies that support continued scientific progress.
Paul Harmatz, MD is an internationally respected physician-scientist whose decades of work in lysosomal storage disorders and other inherited metabolic diseases have contributed substantially to clinical research and the broader understanding of rare diseases. His experience spans investigator-initiated research, multicenter clinical studies, and the development of emerging therapeutic approaches.
Andy Rohrwasser, PhD, MBA brings extensive experience guiding biotechnology companies through scientific innovation, product strategy, and commercialization. As CSO of Myotonic Dystrophy Foundation and former director of Utah Public Health Laboratory and the Utah state newborn screening laboratory, Andy’s unique combination of scientific expertise and business leadership provides valuable perspective on translating emerging technologies into impactful research tools.
Collectively, our Scientific Advisory Board represents decades of experience spanning fundamental research, analytical science, rare disease biology, public health genetics, biotechnology, and strategic innovation.
Since founding Enfanos, our leaders have been dedicated to supporting analytical innovation and research in inborn errors of metabolism. Our portfolio of research use only (RUO) reagents, analytical reference materials, isotopically labeled standards, and quality control materials is designed to provide researchers with reliable, well-characterized tools that support reproducible scientific investigation.
Innovation remains central to everything we do. We believe meaningful advances begin with rigorous science, close collaboration with leading investigators, and continuous investment in research and development. The formation of our Scientific Advisory Board reinforces this commitment and provides Enfanos with exceptional scientific insight as we expand our research portfolio, explore emerging biomarker technologies, and continue preparing for future regulatory milestones.
Contact:
Zackary (Ari) M. Herbst
Chief Science Officer, Enfanos
For research use only. Not for use in diagnostic procedures
Comments